Disruption of LPA ‐LPAR1 pathway results in lung tumor growth inhibition by downregulating B7‐H3 expression in fibroblasts
ConclusionThe present study provided new insights for roles of LPA in CAFs, which could lead to the development of innovative therapies targeting CAFs in the TME. It is also reasonable to postulate a combinatory approach to treat malignant fibrous tumors (such as NSCLC) with LPAR1 antagonists and B7-H3 targeting therapies.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Fanyi Meng,
Zhiyue Yin,
Feifei Lu,
Weipeng Wang,
Hongjian Zhang Tags: ORIGINAL ARTICLE Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Genetics | Lung Cancer | Men | Non-Small Cell Lung Cancer | Study